TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
LYEL

Lyell Immunopharma Inc

Healthcare · Biotechnology

15.60$ -7.2% vs. previous close Closing price · As of: Nov 12, 2026

Statements

Balance Sheet

Lyell Immunopharma Inc (LYEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q3 26), "Total Assets" came in at 274 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LYEL
Line item Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26
750 694 654 619 491 430 385 408 340 351 311 274
555 534 500 450 380 309 282 328 261 267 214 186
146 126 133 100 106 120 99 124 60 91 73 92
546 526 491 441 371 301 277 320 247 254 204 177
95 91 88 89 108 93 87 79 92 77 77 81
35 32 31 34 54 41 37 32 49 37 40 46
6.3 6.7 6.9 7.1 8.0 8.2 8.5 8.8 9.1 9.4 – –
4.8 4.9 4.2 3.6 5.4 3.7 3.4 2.6 2.9 5.5 3.9 4.0
655 603 567 531 383 337 299 329 248 274 234 193
-1,002 -1,063 -1,109 -1,153 -1,345 -1,397 -1,440 -1,479 -1,620 -1,644 -1,688 -1,734
13 13 13 13 13 15 15 18 17 22 23 24

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?